658 related articles for article (PubMed ID: 32943410)
21. Progressive fibrosing interstitial lung disease: treatable traits and therapeutic strategies.
Wongkarnjana A; Scallan C; Kolb MRJ
Curr Opin Pulm Med; 2020 Sep; 26(5):436-442. PubMed ID: 32657838
[TBL] [Abstract][Full Text] [Related]
22. Nintedanib in Patients With Autoimmune Disease-Related Progressive Fibrosing Interstitial Lung Diseases: Subgroup Analysis of the INBUILD Trial.
Matteson EL; Kelly C; Distler JHW; Hoffmann-Vold AM; Seibold JR; Mittoo S; Dellaripa PF; Aringer M; Pope J; Distler O; James A; Schlenker-Herceg R; Stowasser S; Quaresma M; Flaherty KR;
Arthritis Rheumatol; 2022 Jun; 74(6):1039-1047. PubMed ID: 35199968
[TBL] [Abstract][Full Text] [Related]
23. Proteomic biomarkers of progressive fibrosing interstitial lung disease: a multicentre cohort analysis.
Bowman WS; Newton CA; Linderholm AL; Neely ML; Pugashetti JV; Kaul B; Vo V; Echt GA; Leon W; Shah RJ; Huang Y; Garcia CK; Wolters PJ; Oldham JM
Lancet Respir Med; 2022 Jun; 10(6):593-602. PubMed ID: 35063079
[TBL] [Abstract][Full Text] [Related]
24. Effects of nintedanib by inclusion criteria for progression of interstitial lung disease.
Maher TM; Brown KK; Kreuter M; Devaraj A; Walsh SLF; Lancaster LH; Belloli EA; Padilla M; Behr J; Goeldner RG; Tetzlaff K; Schlenker-Herceg R; Flaherty KR;
Eur Respir J; 2022 Feb; 59(2):. PubMed ID: 34210788
[TBL] [Abstract][Full Text] [Related]
25. Impact of antifibrotic therapy on disease progression, all-cause mortality, and risk of acute exacerbation in non-IPF fibrosing interstitial lung diseases: evidence from a meta-analysis of randomized controlled trials and prospective controlled studies.
Li DY; Liu X; Huang JY; Hang WL; Yu GR; Xu Y
Ther Adv Respir Dis; 2024; 18():17534666241232561. PubMed ID: 38414439
[TBL] [Abstract][Full Text] [Related]
26. Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases.
Cottin V; Richeldi L; Rosas I; Otaola M; Song JW; Tomassetti S; Wijsenbeek M; Schmitz M; Coeck C; Stowasser S; Schlenker-Herceg R; Kolb M;
Respir Res; 2021 Mar; 22(1):84. PubMed ID: 33726766
[TBL] [Abstract][Full Text] [Related]
27. Real-World Study Analysing Progression and Survival of Patients with Idiopathic Pulmonary Fibrosis with Preserved Lung Function on Antifibrotic Treatment.
Noor S; Nawaz S; Chaudhuri N
Adv Ther; 2021 Jan; 38(1):268-277. PubMed ID: 33098554
[TBL] [Abstract][Full Text] [Related]
28. Value of CT quantification in progressive fibrosing interstitial lung disease: a deep learning approach.
Koh SY; Lee JH; Park H; Goo JM
Eur Radiol; 2024 Jul; 34(7):4195-4205. PubMed ID: 38085286
[TBL] [Abstract][Full Text] [Related]
29. Interstitial Lung Disease: A Review.
Maher TM
JAMA; 2024 May; 331(19):1655-1665. PubMed ID: 38648021
[TBL] [Abstract][Full Text] [Related]
30. Claims-based Prevalence of Disease Progression among Patients with Fibrosing Interstitial Lung Disease Other than Idiopathic Pulmonary Fibrosis in the United States.
Singer D; Bengtson LGS; Conoscenti CS; Laouri M; Shetty SS; Anderson AJ; Brown KK
Ann Am Thorac Soc; 2022 Jul; 19(7):1112-1121. PubMed ID: 35015982
[No Abstract] [Full Text] [Related]
31. Effect of Nintedanib in Patients with Progressive Pulmonary Fibrosis in Subgroups with Differing Baseline Characteristics.
Kolb M; Flaherty KR; Silva RS; Prasse A; Vancheri C; Mueller H; Sroka-Saidi K; Wells AU;
Adv Ther; 2023 Dec; 40(12):5536-5546. PubMed ID: 37751022
[TBL] [Abstract][Full Text] [Related]
32. Clinical Characteristics and Disease Course of Fibrosing Interstitial Lung Disease Patients in a Real-World Setting.
Kilpeläinen M; Hirvonen T; Perkonoja K; Hirsjärvi S
Medicina (Kaunas); 2023 Jan; 59(2):. PubMed ID: 36837481
[No Abstract] [Full Text] [Related]
33. Progressive Disease With Low Survival in Adult Patients With Pulmonary Fibrosis Carrying Surfactant-Related Gene Mutations: An Observational Study.
Klay D; Grutters JC; van der Vis JJ; Platenburg MGJP; Kelder JC; Tromp E; van Moorsel CHM
Chest; 2023 Apr; 163(4):870-880. PubMed ID: 36370864
[TBL] [Abstract][Full Text] [Related]
34. Nintedanib in Asian patients with progressive fibrosing interstitial lung diseases: Results from the INBUILD trial.
Inoue Y; Wells AU; Song JW; Xu Z; Kitamura H; Suda T; Okamoto M; Müller H; Coeck C; Rohr KB; Kolb M; Brown KK
Respirology; 2023 May; 28(5):465-474. PubMed ID: 36642509
[TBL] [Abstract][Full Text] [Related]
35. Characterization of the PF-ILD phenotype in patients with advanced pulmonary sarcoidosis.
Schimmelpennink MC; Meek DB; Vorselaars ADM; Langezaal LCM; van Moorsel CHM; van der Vis JJ; Veltkamp M; Grutters JC
Respir Res; 2022 Jun; 23(1):169. PubMed ID: 35752806
[TBL] [Abstract][Full Text] [Related]
36. Prevalence and Incidence of Chronic Fibrosing Interstitial Lung Diseases with a Progressive Phenotype in the United States Estimated in a Large Claims Database Analysis.
Olson AL; Patnaik P; Hartmann N; Bohn RL; Garry EM; Wallace L
Adv Ther; 2021 Jul; 38(7):4100-4114. PubMed ID: 34156606
[TBL] [Abstract][Full Text] [Related]
37. Effects of nintedanib on disease progression and safety in Japanese patients with progressive fibrosing interstitial lung diseases: Further subset analysis from the whole INBUILD trial.
Ogura T; Suda T; Inase N; Nishioka Y; Azuma A; Okamoto M; Takizawa A; Ito T; Rohr KB; Inoue Y
Respir Investig; 2022 Nov; 60(6):787-797. PubMed ID: 35927208
[TBL] [Abstract][Full Text] [Related]
38. The Effectiveness of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis, Familial Pulmonary Fibrosis and Progressive Fibrosing Interstitial Lung Diseases: A Real-World Study.
Cameli P; Alonzi V; d'Alessandro M; Bergantini L; Pordon E; Guerrieri M; Refini RM; Sestini P; Bargagli E
Biomedicines; 2022 Aug; 10(8):. PubMed ID: 36009520
[TBL] [Abstract][Full Text] [Related]
39. Disease trajectories in interstitial lung diseases - data from the EXCITING-ILD registry.
Buschulte K; Kabitz HJ; Hagmeyer L; Hammerl P; Esselmann A; Wiederhold C; Skowasch D; Stolpe C; Joest M; Veitshans S; Höffgen M; Maqhuzu P; Schwarzkopf L; Hellmann A; Pfeifer M; Behr J; Karpavicius R; Günther A; Polke M; Höger P; Somogyi V; Lederer C; Markart P; Kreuter M
Respir Res; 2024 Mar; 25(1):113. PubMed ID: 38448953
[TBL] [Abstract][Full Text] [Related]
40. Variability of forced vital capacity in progressive interstitial lung disease: a prospective observational study.
Veit T; Barnikel M; Crispin A; Kneidinger N; Ceelen F; Arnold P; Munker D; Schmitzer M; Barton J; Schiopu S; Schiller HB; Frankenberger M; Milger K; Behr J; Neurohr C; Leuschner G
Respir Res; 2020 Oct; 21(1):270. PubMed ID: 33076914
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
